X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2548) 2548
animals (1611) 1611
humans (1560) 1560
male (897) 897
female (822) 822
endocrinology & metabolism (697) 697
rats (662) 662
mice (516) 516
enzyme inhibitors - pharmacology (461) 461
biochemistry & molecular biology (437) 437
11-beta-hydroxysteroid dehydrogenase type 1 - antagonists & inhibitors (389) 389
11-beta-hydroxysteroid dehydrogenase (385) 385
hydroxysteroid dehydrogenases - antagonists & inhibitors (374) 374
11-beta-hydroxysteroid dehydrogenase type-1 (335) 335
11-beta-hydroxysteroid dehydrogenase type 1 - metabolism (315) 315
pharmacology & pharmacy (282) 282
hormones, hormone substitutes, and hormone antagonists (267) 267
pregnancy (267) 267
expression (258) 258
glucocorticoids (257) 257
abridged index medicus (256) 256
11-beta-hydroxysteroid dehydrogenases (228) 228
structure-activity relationship (222) 222
enzyme inhibitors - chemistry (214) 214
cells, cultured (213) 213
aldosterone (209) 209
hydroxysteroid dehydrogenases - metabolism (209) 209
hypertension (209) 209
steroids (208) 208
11β-hydroxysteroid dehydrogenase (198) 198
physiological aspects (198) 198
adult (197) 197
kinetics (196) 196
metabolism (196) 196
metabolic syndrome (190) 190
enzymes (189) 189
chemistry, medicinal (186) 186
rats, sprague-dawley (186) 186
corticosteroids (184) 184
article (182) 182
cortisol (181) 181
hydrocortisone - metabolism (169) 169
cell biology (168) 168
obesity (168) 168
gene-expression (165) 165
glucocorticoids - metabolism (162) 162
dose-response relationship, drug (161) 161
mineralocorticoid receptor (160) 160
gene expression (155) 155
11-beta-hydroxysteroid dehydrogenase type 2 - metabolism (150) 150
3-beta-hydroxysteroid dehydrogenase (150) 150
physiology (146) 146
progesterone (138) 138
corticosterone (137) 137
molecular structure (136) 136
neurosciences (136) 136
receptors, glucocorticoid - metabolism (134) 134
cell line (133) 133
receptor (133) 133
middle aged (132) 132
rna, messenger - metabolism (132) 132
models, molecular (131) 131
analysis (129) 129
11-beta-hydroxysteroid dehydrogenase type 1 - genetics (128) 128
apparent mineralocorticoid excess (123) 123
3-hydroxysteroid dehydrogenases - antagonists & inhibitors (121) 121
11 beta-hydroxysteroid dehydrogenase (119) 119
blood-pressure (119) 119
enzyme inhibitors - chemical synthesis (118) 118
receptors, mineralocorticoid - metabolism (118) 118
rats, wistar (116) 116
research (116) 116
hormones (115) 115
binding sites (114) 114
liver - enzymology (114) 114
rodents (114) 114
3-hydroxysteroid dehydrogenases - metabolism (112) 112
in vitro techniques (112) 112
endocrine system (111) 111
3-alpha-hydroxysteroid dehydrogenase (109) 109
mice, inbred c57bl (109) 109
inhibition (108) 108
11-beta-hydroxysteroid dehydrogenase type-2 (107) 107
adipose-tissue (107) 107
beta-hydroxysteroid dehydrogenase (107) 107
insulin resistance (107) 107
liver - metabolism (105) 105
testosterone (105) 105
glucocorticoid receptor (103) 103
carbenoxolone - pharmacology (102) 102
dehydrogenases (102) 102
11-beta-hydroxysteroid dehydrogenase type 2 - antagonists & inhibitors (101) 101
toxicology (101) 101
cells (100) 100
diabetes (100) 100
glucocorticoids - pharmacology (99) 99
inflammation (96) 96
cell line, tumor (95) 95
estrogen (95) 95
rat (93) 93
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2788) 2788
Japanese (15) 15
French (12) 12
German (12) 12
Chinese (3) 3
Spanish (3) 3
Russian (2) 2
Dutch (1) 1
Hungarian (1) 1
Italian (1) 1
Norwegian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2012, Volume 55, Issue 5, pp. 2311 - 2323
Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated... 
TARGET | CHEMISTRY, MEDICINAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PURIFICATION | BIOLOGICAL EVALUATION | AKR1C3 | ABIRATERONE ACETATE | 17-BETA-HSD1 | RESISTANT PROSTATE-CANCER | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | Antineoplastic Agents - chemical synthesis | Humans | Male | Structure-Activity Relationship | Hydroxyprostaglandin Dehydrogenases - metabolism | Fenamates - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 20-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 3-Hydroxysteroid Dehydrogenases - metabolism | Antineoplastic Agents - pharmacology | Prostatic Neoplasms - drug therapy | Fenamates - chemistry | Testosterone - biosynthesis | Cyclooxygenase Inhibitors - chemistry | Antineoplastic Agents - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Cyclooxygenase Inhibitors - pharmacology | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Testosterone - antagonists & inhibitors | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Cell Line, Tumor | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Fenamates - chemical synthesis | Cyclooxygenase 1 - metabolism | 3-Hydroxysteroid Dehydrogenases - genetics | Isoenzymes - antagonists & inhibitors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors | Index Medicus
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 03/2016, Volume 472, Issue 1, pp. 231 - 236
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 03/2011, Volume 39, Issue 3, pp. 510 - 521
Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment of human hepatitis C virus infections. In human liver... 
METABOLISM | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NS3 PROTEASE | ALDO-KETO REDUCTASES | CARBONYL REDUCTION | NEUROSTEROIDS | SUPERFAMILY | PHARMACOLOGY & PHARMACY | AGENTS | DEHYDROGENASE | HIV-INTEGRASE INHIBITOR | Liver - enzymology | Proline - metabolism | Stereoisomerism | Humans | Drugs, Investigational - metabolism | Hydroxyprostaglandin Dehydrogenases - metabolism | Urea - chemistry | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Drugs, Investigational - chemistry | Serine Proteinase Inhibitors - chemistry | Cytochrome P-450 CYP3A - genetics | Urea - analogs & derivatives | 3-Hydroxysteroid Dehydrogenases - metabolism | Hydroxysteroid Dehydrogenases - metabolism | Urea - metabolism | Molecular Structure | Oligopeptides - chemistry | Recombinant Proteins - metabolism | Oxidation-Reduction | Proline - analogs & derivatives | Subcellular Fractions - drug effects | Enzyme Inhibitors - pharmacology | Serine Proteinase Inhibitors - metabolism | Hydroxysteroid Dehydrogenases - genetics | Oligopeptides - metabolism | Subcellular Fractions - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Proline - chemistry | Hepacivirus - enzymology | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Cytochrome P-450 CYP3A Inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Cytochrome P-450 CYP3A - metabolism | Biotransformation - drug effects | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Kinetics | 3-Hydroxysteroid Dehydrogenases - genetics | Viral Nonstructural Proteins - antagonists & inhibitors | Subcellular Fractions - enzymology | Index Medicus
Journal Article
Oncology Reports, ISSN 1021-335X, 03/2017, Volume 37, Issue 4, pp. 2025 - 2032
Resistance to anticancer medications often leads to poor outcomes. The present study explored an effective approach for enhancing chemotherapy targeted against... 
aldo-keto reductase | cisplatin | mefenamic acid | 5-FU | Cisplatin, 5-FU | Mefenamic acid | Aldo-keto reductase | HUMAN OVARIAN | AKR1C3 | CISPLATIN RESISTANCE | TUMOR-CELLS | CHEMOTHERAPY | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | LUNG-CANCER | CARCINOMA CELL-LINE | ONCOLOGY | SUPERFAMILY | EXPRESSION | 20-Hydroxysteroid Dehydrogenases - biosynthesis | 3-Hydroxysteroid Dehydrogenases - biosynthesis | 20-Hydroxysteroid Dehydrogenases - genetics | Humans | Hydroxyprostaglandin Dehydrogenases - biosynthesis | Hydroxysteroid Dehydrogenases - genetics | Hydroxyprostaglandin Dehydrogenases - genetics | Cisplatin - administration & dosage | Neoplasms - drug therapy | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Fluorouracil - administration & dosage | 20-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Neoplasms - genetics | Aldo-Keto Reductase Family 1 Member C3 | Mefenamic Acid - administration & dosage | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxysteroid Dehydrogenases - biosynthesis | Gene Expression Regulation, Neoplastic - drug effects | HeLa Cells | Oxidoreductases | 3-Hydroxysteroid Dehydrogenases - genetics | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Patient outcomes | Genetic aspects | Drug resistance | Gene expression | Health aspects | Methods | Cancer | Studies | Enzymes | Oxidative stress | Chemotherapy | Genes | Rodents | Prostate | Experiments | Cancer therapies | Deoxyribonucleic acid--DNA | Apoptosis | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 01/2017, Volume 16, Issue 1, pp. 35 - 44
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully... 
STEROIDOGENIC ENZYME AKR1C3 | CYP17A1 INHIBITION | ONCOLOGY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | INCREASED SURVIVAL | ENZALUTAMIDE RESISTANCE | ANTITUMOR-ACTIVITY | ANDROGEN RECEPTOR GENE | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | Prostatic Neoplasms - metabolism | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Male | Androstenes - pharmacology | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Prostatic Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | 3-Hydroxysteroid Dehydrogenases - metabolism | Transcription, Genetic | Prostatic Neoplasms - drug therapy | Disease Models, Animal | Prostatic Neoplasms - pathology | Gene Expression | Antineoplastic Agents, Hormonal - pharmacology | Cell Transformation, Neoplastic - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Animals | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Mice | Cell Transformation, Neoplastic - drug effects | 3-Hydroxysteroid Dehydrogenases - genetics | Neoplasm Staging | Medical research | Transcription | Medical services | Clinical trials | Activation | Signaling | Androgens | Synthesis | Steroidogenesis | Indomethacin | Inhibition | Prostate cancer | Prostate | Cancer | Index Medicus | AKR1C3 | prostate cancer | intracrine androgens | abiraterone | indomethacin
Journal Article
Journal Article
Journal Article
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 07/2017, Volume 171, pp. 270 - 280
17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5) is an important enzyme associated with sex steroid metabolism in hormone-dependent cancer. However,... 
GRP78 | PGK1 | 17β-HSD5 | Cell viability | Breast cancer cell proteome | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | C-MYC | 17 beta-HSD5 | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE | KETO REDUCTASE SUPERFAMILY | ENDOCRINOLOGY & METABOLISM | RESISTANCE | MYC ONCOGENE EXPRESSION | PROGNOSTIC MARKER | PHOSPHOGLYCERATE KINASE | CARCINOMA | PROTEOMICS | Receptors, Estrogen - metabolism | Cell Proliferation | Humans | Two-Dimensional Difference Gel Electrophoresis | Gene Expression Regulation, Neoplastic | Heat-Shock Proteins - antagonists & inhibitors | Neoplasm Proteins - antagonists & inhibitors | Gene Expression Profiling | Neoplasm Proteins - metabolism | Hydroxyprostaglandin Dehydrogenases - metabolism | NM23 Nucleoside Diphosphate Kinases - genetics | NM23 Nucleoside Diphosphate Kinases - metabolism | Breast Neoplasms - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Heat-Shock Proteins - genetics | Phosphoglycerate Kinase - chemistry | MCF-7 Cells | RNA Interference | 3-Hydroxysteroid Dehydrogenases - metabolism | Female | Proteomics - methods | Hydroxyprostaglandin Dehydrogenases - chemistry | Neoplasm Proteins - genetics | Phosphoglycerate Kinase - genetics | NM23 Nucleoside Diphosphate Kinases - chemistry | Cell Survival | Heat-Shock Proteins - metabolism | Neoplasm Proteins - chemistry | Proto-Oncogene Proteins c-myc - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Image Processing, Computer-Assisted | Aldo-Keto Reductase Family 1 Member C3 | Breast Neoplasms - pathology | 3-Hydroxysteroid Dehydrogenases - chemistry | Proto-Oncogene Proteins c-myc - genetics | Enzyme Activation | 3-Hydroxysteroid Dehydrogenases - genetics | Proto-Oncogene Proteins c-myc - chemistry | Heat-Shock Proteins - chemistry | Phosphoglycerate Kinase - metabolism | Ubiquitin | Care and treatment | Breast cancer | Cancer | Apoptosis | Analysis | Physiological aspects | Development and progression | Cellular signal transduction | Metastasis | Gene expression | Estradiol | Mass spectrometry | Gel electrophoresis | Invasiveness | RNA-mediated interference | c-Myc protein | Estrogen receptors | Mass spectroscopy | siRNA | Myc protein | Phosphoglycerate kinase | Metastases | Proteins | Breast carcinoma | Cell growth | Ubiquitination | Protein folding | Cell lines | Phosphoglycerate kinase 1 | Transduction | Nucleoside-diphosphate kinase | Index Medicus
Journal Article
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 08/2014, Volume 278, Issue 3, pp. 238 - 248
Pharmacokinetic drug resistance is a serious obstacle that emerges during cancer chemotherapy. In this study, we investigated the possible role of aldo-keto... 
Anthracyclines | Aldo-keto reductase 1C3 | Drug resistance | Metabolism | Enzyme induction | DOXORUBICIN | TUMOR-CELLS | INDUCTION | STEROID-HORMONE | DAUNORUBICIN | ENDOMETRIAL CANCER | BREAST-CANCER | 5 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | PROSTATE-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MCF-7 CELLS | Antibiotics, Antineoplastic - pharmacology | Humans | Daunorubicin - agonists | Daunorubicin - pharmacology | Idarubicin - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Neoplasm Proteins - metabolism | Anthracyclines - agonists | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Anthracyclines - pharmacology | Biotransformation | Anthracyclines - metabolism | Enzyme Induction - drug effects | 3-Hydroxysteroid Dehydrogenases - metabolism | Doxorubicin - metabolism | Daunorubicin - metabolism | Neoplasm Proteins - genetics | Antibiotics, Antineoplastic - agonists | Carcinoma - drug therapy | Idarubicin - metabolism | Recombinant Proteins - metabolism | Cell Survival - drug effects | Oxidation-Reduction | Flavanones - pharmacology | Enzyme Inhibitors - pharmacology | Recombinant Proteins - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Drug Synergism | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Kinetics | 3-Hydroxysteroid Dehydrogenases - genetics | Antibiotics, Antineoplastic - metabolism | Idarubicin - agonists | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Physiological aspects | Chemotherapy | Cancer cells | Cancer | Index Medicus | CARBONYLS | METABOLISM | NEOPLASMS | ENZYMES | DRUGS | TOXICITY | INCUBATION | 60 APPLIED LIFE SCIENCES | ENZYME INDUCTION | CHEMOTHERAPY
Journal Article
Chemical Research in Toxicology, ISSN 0893-228X, 03/2016, Volume 29, Issue 3, pp. 398 - 405
Journal Article